The National Institute of Allergy and Infectious Diseases (NIAID) awarded Duke University a $1,326,630 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a clinical trial on new treatment strategies for talaromycosis, a deadly fungal infection endemic to Southeast Asia. The project, titled "LIPOSOMAL AMPHOTERICIN B AND FLUCYTOSINE ANTIFUNGAL STRATEGIES FOR TALAROMYCOSIS (LAMB-FAST)," aims to determine if a single high-dose of liposomal amphotericin B is superior to the standard 14-day course of amphotericin B deoxycholate, and if adding flucytosine further improves outcomes. The grant will also explore a related sub-study on optimizing itraconazole prophylaxis for preventing talaromycosis relapse in people living with HIV. This research is expected to have a significant impact on treatment guidelines for this life-threatening fungal disease.
Generated 1/28/25, 7:43 AM